Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Total Current Liabilities: 2022-2025

Historic Total Current Liabilities for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $1.8 million.

  • InMed Pharmaceuticals' Total Current Liabilities rose 8.29% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 8.29%. This contributed to the annual value of $1.8 million for FY2025, which is 6.70% down from last year.
  • InMed Pharmaceuticals' Total Current Liabilities amounted to $1.8 million in FY2025, which was down 6.70% from $2.0 million recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Total Current Liabilities high stood at $3.3 million for FY2022, and its period low was $1.8 million during FY2025.
  • In the last 3 years, InMed Pharmaceuticals' Total Current Liabilities had a median value of $2.0 million in 2024 and averaged $1.9 million.
  • Data for InMed Pharmaceuticals' Total Current Liabilities shows a maximum YoY crashed of 39.73% (in 2023) over the last 5 years.
  • InMed Pharmaceuticals' Total Current Liabilities (Yearly) stood at $3.3 million in 2022, then plummeted by 39.73% to $2.0 million in 2023, then declined by 1.44% to $2.0 million in 2024, then dropped by 6.70% to $1.8 million in 2025.